AN OPEN-LABEL, SINGLE ARM, MULTI-CENTER EXTENSION STUDY EVALUATING LONG-TERM SAFETY, TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS
- Registry ID
- COMB157G2399
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2019-11-27
- Last update
- 2018-10-15
Conditions
- RELAPSING-REMITTING MULTIPLE SCLEROSIS
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY, COMPARING THE EFFICACY AND SAFETY OF REMIBRUTINIB VERSUS TERIFLUNOMIDE IN PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS, FOLLOWED BY EXTENDED TREATMENT WITH OPEN-LABEL REMIBRUTINIB
- AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS
- A PHASE 3B, 12-MONTH, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB019, DACLIZUMAB, IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) SWITCHING FROM NATALIZUMAB (SUSTAIN)
View on source registry